Wegovy: Daily Pill Shows 13% Weight Loss in Groundbreaking Trial
Wegovy Demonstrates Promising Weight Loss Results
A daily weight loss pill from Novo Nordisk, known as Wegovy, has shown the potential to reduce body weight by up to 13% after only three months in a Phase 1 clinical trial. This groundbreaking news was presented during the European Association for the Study of Diabetes annual meeting in Spain.
Rapid Weight Loss Rate
The experimental pill, amycretin, demonstrated a weight loss rate that is approximately double that of existing GLP-1 agonists. Dr. Christopher McGowan, a prominent gastroenterologist overseeing a weight loss clinic in North Carolina, remarked on its potential, stating, “It shows potential promise.”
Expert Opinions on Wegovy
Dr. Susan Spratt, senior medical director for the Population Health Management Office at Duke Health, expressed that the results are indeed impressive, lending credibility to the expectations surrounding Wegovy's efficacy.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.